Previous 10 | Next 10 |
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that members of management will participate at the Morgan Stanley Global Healthcare Conference held on September 15, 2020. The presentation will begin at 4:15 PM Eastern Time and a live webcast will be acc...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Lidocaine Patch, 5%. Lidocaine Patc...
WARSAW, Ind., Aug. 12, 2020 (GLOBE NEWSWIRE) -- WishBone Medical, Inc., a leader in pediatric orthopedic medical devices, is pleased to announce the appointment of Jeff George, global healthcare executive and investor, to the company’s board of directors, effective August 12, 2020. ...
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2020 Earnings Conference Call August 06, 2020, 08:30 ET Company Participants Anastasios Konidaris - EVP & CFO Chirag Patel - Co-Founder, Co-CEO, President & Director Chintu Patel - Co-Founder, Co-CEO & Director Joseph Todisco -...
Image source: The Motley Fool. Amneal Pharmaceuticals, Inc. (NYSE: AMRX) Q2 2020 Earnings Call Aug 6, 2020 , 8:30 a.m. ET Operator Continue reading
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...
‒ Q2 2020 Net Revenue of $465 million; GAAP Net Loss of $(12) million; Diluted Loss per Share of $(0.08) ‒ ‒ Q2 2020 Adjusted Net Income (1) of $38 million; Adjusted EBITDA (1) of $101 million; Adjusted Diluted EPS (1) of $0.13‒ ‒ M...
Eastman Kodak Co.’s (NASDAQ: KODK) stock tripled following the announcement that the once-bankrupt company had received a $765 million loan from the Trump administration to fund a pharmaceutical ingredients company. A MarketWatch article written by Jaimy Lee noted that “Kodak, wh...
BRIDGEWATER, N.J., July 14, 2020 (GLOBE NEWSWIRE) -- Cosette Pharmaceuticals, Inc. (“Cosette” or the “Company”), a privately held specialty generic pharmaceutical company primarily focused on extended topical and suppository products, announced today the appointm...
DBV Technologies Reports Positive Extension Study Results DBV Technologies (DBVT) reported positive results from its open label extension of the Phase 3 study. The data showed that the participants underwent sustained clinical benefit with an extra two years of treatment with Viaskin Pea...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...